Oligodendroglioma is a primary malignant brain cancer that develops from oligodendrocytes. Oligodendroglioma is one of the more common types of glioma (which also includes glioblastoma multiforme and astrocytoma). It is a rare tumor that strikes people of all ages; on average, 1,500 new cases are diagnosed per year in the United States. Rarely, families with multiple affected members have been reported, suggesting that a predisposition for oligodendroglioma can be inherited from blood relatives. Because oligodendroglioma is so rare, it has not been well-studied, due in part to a lack of available biospecimens and data for research use.
What are the goals of this project?
The goal of this project is to generate whole genome sequencing with paired RNA sequencing for a cohort of Oligodendroglioma across pediatric, adolescent and adult cohort.
What is the impact of this project?
This project will create the largest open access cohort of oligodendroglioma data.
Why the CBTN request is important to this project?
There are no other specimens available in the pediatric arena
The Children's Brain Tumor Network contributed to this project by providing DNA and RNA samples for sequencing.
Adam Resnick, PhD
Adam Resnick is the Director of Data Driven Discovery in Biomedicine (D3b) at Children’s Hospital of Philadelphia (CHOP) responsible for leading a multidisciplinary team to build and support a scalable, patient-focused healthcare and educational discovery ecosystem on behalf of all children. He i
Children’s Hospital of Philadelphia